Cost-Effectiveness of SGLT2i plus GLP-1RAs vs. SGLT2i in Patients with Chronic Kidney Disease

Related

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• SGLT2 inhibitors raise genital but not urinary infection risk

  Clinical Pharmacology and Therapeutics · 4 Oct 2026

• China faces $6.45 trillion kidney disease burden through 2060

  Research Square · 4 Oct 2026